RPL554

January 11, 2019January 21, 2019

WHO Approves Ensifentrine as Name for Potential Inhaled Treatment Now in Clinical Trials

cystic fibrosis, News

The World Health Organization (WHO) approved ensifentrine as the recommended name to identify the cystic fibrosis (CF) treatment candidate RPL554. Verona Pharma’s ensifentrine is an inhaled inhibitor of the enzymes phosphodiesterase ... Read more

November 6, 2018November 6, 2018

#NACFC2018 – RPL554 Shows Promising Results in CF Studies

cystic fibrosis, News

Positive data from preclinical and Phase 2a studies evaluating the investigational cystic fibrosis (CF) treatment RPL554 were presented at the 2018 North American Cystic Fibrosis Conference (NACFC) in Denver, Colorado (Oct. ... Read more

March 7, 2018March 7, 2018

Verona Therapy Improves CF Patients’ Lung Function, Phase 2a Trial Shows

cystic fibrosis, News

Verona Pharma’s nebulized RPL554 can significantly improve lung function in patients with cystic fibrosis, according to top-line data from a Phase 2a clinical trial. The latest results revealed that ... Read more

August 14, 2017August 14, 2017

CF Patients in Europe Wanted for Phase 2 Trial of Investigational Therapy RPL554

cystic fibrosis, News

Verona Pharma recently announced the company’s accomplishments in the last six months, including an update to the company’s clinical trial in cystic fibrosis (CF) and positive interim results for its investigational ... Read more

April 6, 2017April 6, 2017

First Patient Dosed in Phase 2a Clinical Trial of Verona Pharma’s RPL554 for Cystic Fibrosis

cystic fibrosis, News

The first patient has been dosed in a Phase 2 clinical trial evaluating RPL554 as a treatment for cystic fibrosis (CF), according to its maker, Verona Pharma. RPL554 is a ... Read more

November 7, 2016November 7, 2016

CF Trust Award to Support Clinical Study of Possible Respiratory Therapy, RPL554

News

Verona Pharma recently announced that it has received its second Venture and Innovation Award from the U.K. Cystic Fibrosis Trust. The award will help fund a Phase 2 clinical trial to investigate RPL554 ... Read more

October 1, 2014October 1, 2014

RPL554 Emerging As Viable Cystic Fibrosis Therapy

News

Data supporting a promising, new treatment for Cystic Fibrosis (CF) developed by Verona Pharma will be presented for the first time at the 28th Annual North American Cystic Fibrosis ... Read more

Pin It on Pinterest